Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Contributed by: Business Wire

Logo

Tags

Research

Mental Health

FDA

Clinical Trials

Biotechnology

General Health

Pharmaceutical

Health

Science

Other Science

Psych Congress 2026

More Like This

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin